D0435 - Safety and Efficacy of the Novel EndoRotor Device for the Treatment of Walled-Off Pancreatic Necrosis (WOPN): A Systematic Review and Meta-Analysis

Daryl Ramai, MD, MSc¹, Zohaib Ahmed, MD, MPH², Smit Deliwala, MD³, Daniel Mozell, MD⁴, Antonio Facciorusso, MD, PhD⁵, Amanda Morgan, MD⁶, Andrea Anderloni, MD⁷, Monique Barakat, MD, PhD⁸, Yaseen Alastal, MD, MPH², Douglas G. Adler, MD, FACG^9
1University of Utah, Salt Lake City, UT; ²University of Toledo, Toledo, OH; ³Michigan State University at Hurley Medical Center, Flint, MI; ⁴Elmhurst Hospital, Elmhurst, NY; ⁵University of Foggia, Foggia, Puglia, Italy; ⁶Rocky Vista University, Ivins, UT; ⁷IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy; ⁸Stanford University, Stanford, CA; ⁹Centura Health-Porter Adventist Hospital, Salt Lake City, UT

Introduction: Debridement of infected walled-off pancreatic necrosis (WOPN) is indicated to treat and prevent sepsis-related multi-organ failure. The lack of dedicated and effective accessories for WOPN debridement results in the need for time-consuming repetitive procedures. The aim of this study was to evaluate the efficacy and safety of the EndoRotor® powered endoscopic debridement system to remove solid debris under direct endoscopic visualization.

Methods: Search strategies were developed for PubMed, EMBASE, and Cochrane Library databases from inception through June 2022, in accordance with PRISMA and MOOSE guidelines. Outcomes of interest included technical success defined as successful use of device for debridement, clinical success defined as complete debridement and cyst resolution, and procedure-related adverse events. A random effects model was used for analysis and results were expressed as Odds ratio (OR) along with 95% confidence interval (CI).

Results: A total of 8 studies (n = 91 patients) were included. The most common etiology of WOPN was biliary (30%). Mean WOPN size was 154.6 ± 34.0 mm, while mean procedure time was 71.4 minutes. LAMS were used to create a cystgastrostomy for 73.6% of cases with the remaining cases relying upon a placement of plastic stents (24.2%) and self-expanding metal stents (SEMS) (2.2%). The mean number of necrosectomy sessions required was 2.2 (range 1 to 7). The pooled rate of clinical success was 97% (95% CI 93-100%, I2 = 0%) with a pooled technical success rate of 97% (93-100%, I2 Z54%). The pooled procedure-related adverse event rate was 7% (2-12%, I2 = 0%), which included procedure-associated bleeding, pneumoperitoneum, peritonitis, pleural effusion, and dislodgement of LAMS. Overall publication bias was considered low.

Discussion: Our study illustrates that the novel EndoRotor device appears to be safe and effective for treating pancreatic necrosis. Patients undergoing endoscopic necrosectomy with the EndoRotor appear to require less debridement sessions when compared with studies using conventional instruments.



Disclosures:


Daryl Ramai, MD, MSc¹, Zohaib Ahmed, MD, MPH², Smit Deliwala, MD³, Daniel Mozell, MD⁴, Antonio Facciorusso, MD, PhD⁵, Amanda Morgan, MD⁶, Andrea Anderloni, MD⁷, Monique Barakat, MD, PhD⁸, Yaseen Alastal, MD, MPH², Douglas G. Adler, MD, FACG⁹. D0435 - Safety and Efficacy of the Novel EndoRotor Device for the Treatment of Walled-Off Pancreatic Necrosis (WOPN): A Systematic Review and Meta-Analysis, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.